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Bethesda, Maryland 20892 mucosa (Belyakov et al., 2001). While in these studies
protection correlated with the induction of local CD8
CTL, antibody at the mucosal surface may also contri-
bute to protection against mucosal transmission of SIVMucosal tissues are the primary site of natural HIV
transmission and a major reservoir for HIV replication. (Baba et al., 2000; Mascola et al., 2000). These results
provide strong support for development of new genera-Targeting immune responses to the mucosal entry site
before viral dissemination could protect and also clear tion vaccines that induce local mucosal CD8 CTL, as
well as mucosal secretory IgA against HIV.viral reservoirs. Recent understanding of mucosal HIV
transmission and of chemokines and integrins in mu-
cosal trafficking can aid design of new strategies to Mucosal Transmission of HIV
enhance AIDS vaccine efficacy. Natural transmission of HIV is through a mucosal sur-
face, and prevention of mucosal transmission is a crucial
goal of HIV vaccine development. In homosexual men,
Introduction who represent the vast majority of HIV-infected patients
Important new information has emerged regarding the in Europe and North America, the intestinal (rectal) mu-
role of the gastrointestinal mucosa in HIV-1 infection. cosa is an important portal of entry of HIV. However,
This information is derived from the fields of molecular SIV studies in macaques suggest that HIV/SIV infection
and cellular immunology and virology, including both can occur also through oro-pharyngeal, cervical/vagi-
basic and clinical investigations. Given the critical need nal, and upper gastrointestinal mucosa (reviewed by
for an AIDS vaccine, these discoveries in mucosal trans- Kozlowski and Neutra, 2003). In the absence of mucosal
mission and dissemination, mucosal pathogenesis of disruption from trauma, proposed routes of HIV-1 entry
HIV infection, and the protective role of mucosal immu- into the mucosal lamina propria include M cells, den-
nity come at an opportune time for the development of dritic cells, and epithelial cells (Figure 1) (Neutra et al.,
a new generation of mucosal AIDS vaccines. 1996). In the SIV model, atraumatic inoculation of SIV
The gastrointestinal and vaginal mucosa play a funda- into the oral cavity leads to rapid infection of the tonsils,
mental role in early HIV disease by serving as a site for which are a rich source of M cells, suggesting M cell
virus entry (most often rectal or vaginal) (Kozlowski and uptake and transport of the virus (Baba et al., 1996;
Neutra, 2003; Neutra et al., 1996), an initial and ultimately Stahl-Hennig et al., 1999), although proof of transmis-
predominant site of virus replication and amplification sion through M cells remains to be established. M cells
(small intestine), and the initial site of CD4 T cell deple- are present in the small intestine and rectum as well,
tion (small intestine) (Veazey et al., 1998). Thus, AIDS but not the genital mucosa (Kozlowski and Neutra, 2003).
should be considered as a disease of the mucosal im- Alternatively, recent evidence indicates that dendritic
mune system. In particular, studies of SIV infection of cells bind HIV-1 envelope gp120 through a C type lectin
Rhesus macaques suggest that, regardless of the route (DC-SIGN), suggesting that dendritic cells that squeeze
of infection, the gastrointestinal mucosa, not the periph- between “tight” epithelium may capture HIV-1 and de-
eral lymphoid tissue, is the initial and predominant tissue liver it to underlying T cells, resulting in dissemination
site of HIV-1/SIV infection, as indicated by the early local to secondary lymphoid organs (Cameron et al., 1992;
accumulation of SIV-infected lymphocytes and the high Geijtenbeek et al., 2000) (Figure 1). This pathway may
viral load in the intestinal mucosa (Veazey et al., 1998). In be more important in the genital tract, which lacks M
addition, early after intravaginal inoculation in macaques cells (Kozlowski and Neutra, 2003). HIV can cross a tight
(during the first 2–7 days), SIV is localized to mucosal epithelial barrier by transcytosis during contact between
(endocervical) tissue without dissemination to the sys- HIV-infected cells and the apical surface of an epithelial
temic circulation (Spira et al., 1996; Zhang et al., 1999). cell (Bomsel, 1997) (Figure 1). The process of trans-
Therefore, these studies suggest that a vaccine that cytosis can be inhibited by induction of mucosal anti-
induces local mucosal immunity, in particular CD8CTL, bodies (dimeric IgA or IgM against HIV envelope protein).
may control viral replication within local tissues prior to Mechanisms of interaction between HIV-1 infected cells
systemic dissemination. Support for this possibility was and epithelial cells of human mucosa are not well under-
provided by our recent study demonstrating that local stood.
mucosal CTL, induced by mucosal immunization in Virtually all strains of HIV-1 use CD4 as a receptor on
mice, can protect against mucosal challenge with virus, target cells, but strains of HIV-1 have been divided into
while systemic CD8 CTL are not sufficient to protect two categories based on their coreceptor usage: “R5”
against mucosal transmission (Belyakov et al., 1998a). strains using the chemokine receptor CCR5 as a core-
ceptor and primarily infecting macrophages and den-
dritic cells, and “X4” strains using CXCR4 as a core-*Correspondence: belyakov@mail.nih.gov
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Figure 1. Mucosal Transmission of HIV/SIV
HIV/SIV entry into the mucosal lamina propria is mediated by M cells (specialized epithelial cells), dendritic cells, and epithelial cells. Experimental
SIV infection through the oral cavity leads to rapid infection of the tonsils, which are a rich source of M cells, suggesting M cells take up and
transport SIV. M cells can mediate the transport of antigen in the intestine as well, but are absent in the vaginal mucosa. Dendritic cells bind
HIV-1 gp120 through DC-SIGN and can squeeze between epithelial junctions to capture HIV/SIV and disseminate it to lymphoid organs. This
mechanism may predominate in the genital tract, and subepithelial DC are the major target of viral replication after cervicovaginal SIV infection.
HIV-infected cells can cross an epithelial barrier by transcytosis in the human small intestine, which expresses galactosylceramide and CCR5
but not CXCR4 and can selectively transfer R5 but not X4 virus.
ceptor and primarily infecting CD4 T cells that express 2003). For example, the major target of HIV in the upper
gastrointestinal tract is lamina propria lymphocytes,this chemokine receptor. In mucosal transmission of
HIV-1, the initial infection is usually an R5, not X4, strain, which express CCR5 and CXCR4, but not macrophages,
which have been reported to be paradoxically CCR5even when the donor has both viruses (Wolinsky et al.,
1992; Zhu et al., 1993). A recent study by Meng et al. negative in the upper GI tract in contrast to macro-
phages elsewhere (Meng et al., 2002). After cervicovagi-suggests that the epithelial cells of the small intestine
express galactosylceramide (which can serve as an al- nal infection with SIV in macaques, subepithelial DC are
the first and major site of early viral replication. DC alsoternative receptor substituting for CD4 in these cells that
lack CD4) and CCR5, but not CXCR4, and can selectively can migrate to the T cell area in regional mucosal tissue
and infect T lymphocytes.transfer R5, but not X4, virus through a probable trans-
cytosis mechanism without becoming infected (Meng The period of local (mucosal) replication and local
viral interaction with mucosal cells without systemic dis-et al., 2002) (Figure 1). They propose this selectivity as a
potential mechanism for selective R5 virus transmission. semination is crucial for potential generation of preven-
tive local immune responses (antibody and CD8 CTL),Accordingly, production or delivery of CC chemokines
(which bind CCR5) or antibodies that block viral interac- which can eliminate much of the viral load after mucosal
transmission and reduce disease. Zhang et al. (1999)tion through CCR5 may be especially effective as an
immunological mechanism of protection (Lehner, 2002). studied SIV replication by in situ hybridization in the
local mucosal site (endocervical tissue) and systemicIn contrast, blood CD4T cells are predominantly CXCR4
and are targeted by X4 viruses. lymphoid tissues after intravaginal inoculation in ma-
caques. The first detection of low levels of viral RNAAfter mucosal transmission of HIV, the first detectable
sites of viral replication are intraepithelial and subepi- was observed in the endocervical tissue. The amount of
viral RNA in the endocervical region increased betweenthelial DC, CD4 T cells, and macrophages. However,
the initial cellular target of HIV replication depends on days 3 and 7. However, the first SIV RNA in the draining
and distant lymph nodes and bone marrow was foundthe anatomical site of infection (Kozlowski and Neutra,
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on day 12 after mucosal inoculation (Zhang et al., 1999). express high amounts of intestinal homing integrin47.
A few cells in the colon or other mucosal tissues expressIn another study, after intravaginal inoculation of SIV,
CCR9, but it is most highly expressed by all CD4 andinfected cells were detected in the draining internal
CD8 T lymphocytes in the small intestine (Kunkel etiliac lymph nodes within 2 days and in the blood within
al., 2000). Activated B cells express CCR5, IgA, and5 days (Spira et al., 1996). In either case, immunological
intestinal homing receptors 47 and CCR10, the ligandclearance mechanisms may have a few days to eradi-
for CCL28/MEC (Kunkel et al., 2003), and some of themcate the virus locally before it disseminates widely.
also express CCR9 and react with CCL25. Thus, CCL25Understanding early events of interaction between
is an attractive target for therapeutic recruitment of bothHIV and mucosa will help in the development of new
T and B lymphocytes to the gut, especially the smallmucosal vaccines and prevention of HIV transmission
intestine.through mucosal surfaces.
In contrast to an earlier belief in the unity of the muco-
sal immune system, it is now clear that different mucosalTissue-Specific Homing Directed by Chemokines
compartments use different homing receptors, despiteand Integrins Necessitates Appropriate Routes
some crosstalk between them. Thus, in contrast to theof Immunization for Protective Mucosal Immunity
situation in the small intestine, MAdCAM-1, the ligandA critical finding is that chemokine receptors are very
for 47 integrin, has not been found in genital tractimportant for HIV-1 transmission and AIDS pathogene-
mucosa, so expression of 47 integrin by T cells doessis. The two main chemokine receptors that define dif-
not promote trafficking to these sites, accounting forferent tropisms of HIV-1, CXCR4, and CCR5 also define
the limited trafficking observed between these compart-different populations of migratory T cells, naive, and
ments (Kozlowski and Neutra, 2003). Also, lymphocytesmemory or effector T cells. Activated and resting mem-
from tonsil, lung, inflamed liver, normal and inflamedory T cells that express both CD4 and CCR5 are an
skin, breast milk, and seminal fluid are CCR9 and doinitial viral target, but both naive and memory CD4 cells
not home to the small intestine where CCL25 bindingare targeted by virus capable of using CXCR4 for entry.
to CCR9 is an important attractant. Indeed, even theThe mechanism of T cell trafficking to and among
colon has a relative dearth of CCR9-expressing T cellsdifferent mucosal sites is not completely understood
in contrast to the small intestine. Thus, effector and(reviewed by Kunkel and Butcher, 2002). Trafficking ap-
memory T cell homing to the gut may be different inpears to be regulated by chemokine receptors and integ-
different segments of the gastrointestinal tract. There-rins on the T cells responding to different chemokines
fore, targeting the mucosal site relevant to a particularand addressins, respectively, that differ from site to site.
disease may be critical in vaccine design.Expression of these chemokine receptors and integrins
It was found that mucosal immunization with an HIVis determined by the microenvironment of the local tis-
vaccine induced CD8 CTL responses in both mucosalsue where they differentiate into effector or memory
and systemic lymphoid tissues, whereas systemic im-T cells. Naive T lymphocytes may traffic to the regional
munization induced CD8 CTL predominantly in sys-lymph nodes where they are attracted by chemokines
temic sites (Belyakov et al., 1998b; Berzofsky et al.,
CCL21, CCL19, and CXCL13, which bind to CXCR5 on
2001; Kozlowski and Neutra, 2003). Similar asymmetry
these naive cells (Campbell and Butcher, 2002a), or to
was subsequently also seen after immunization with re-
the skin (see below), or the mucosa (Figure 2). When
combinant salmonella (Shata et al., 2001) or with DNA
T cells are stimulated by antigen in the gut-inductive encapsulated in poly (dl-lactide coglycolide) micropar-
lymphoid sites, such as Peyer’s patches, they acquire ticles (Kaneko et al., 2000). This asymmetry between
the 47 integrin, which mediates homing of memory mucosal and systemic immunization indicates that anti-
T cells back to the gut. The47 integrin’s ligand “muco- gen-specific T cells in mucosal sites (after mucosal im-
sal addressin cell adhesion molecule” (MAdCAM)-1 is munization/mucosal infection) can migrate not only to
expressed on postcapillary venules in the lamina propria mucosal effector sites (lamina propria, mucosal epithe-
(LP) of the intestine (Figure 2) and mediates homing of lium) but also to systemic lymphoid tissue as well. How-
T cells to the intestinal LP. ever, lymphocytes from the systemic circulation are lim-
At the chemokine receptor level, CCR9, which binds ited in their ability to migrate to mucosal lymphoid tissue.
the chemokine CCL25 (also known as TECK, thymus- Consistent with this idea, in a recent study by Camp-
expressed chemokine), has been identified as a gut- bell and Butcher (2002b), CD4 T cells responding to
homing chemokine receptor that marks essentially all antigen in mesenteric lymph nodes and Peyer’s patches
CD4 and CD8 memory or effector T lymphocytes in were shown to express high levels of 47 and acquire
the small intestine (Zabel et al., 1999) (Figure 2). CCL25 responsiveness to the intestinal chemokine CCL25/
is found in the intestinal epithelium and in the vascular TECK and migrate into the intestinal lamina propria. In
endothelium within the human small intestine and plays contrast, CD4 cells activated in cutaneous lymph nodes
a role in lymphocyte entry into the small intestine (Kunkel upregulate the adhesion molecule P-selectin ligand
et al., 2000). It is likely that gradients of CCL25 attract (P-lig), which targets P-selectin in inflamed skin, and
CCR9 lymphocytes to the small intestine and then downregulate 47 (Campbell and Butcher, 2002b).
these are retained there through interaction of 47 These molecules define largely nonoverlapping popula-
integrin with MAdCAM-1, so the two receptors act syn- tions of CD4 T cells. These data imply that HIV/SIV-
ergistically. After activation in the small intestine, CD8 specific 47 T cells and B cells, which are capable
and CD4 T cells selectively express CCR9 (Svensson et of migrating into the mucosa, will be optimally generated
al., 2002), whereas cells which are activated in peripheral by application of antigen on the mucosal surface. In
support of this hypothesis, a study by Cromwell et al.lymph nodes do not express CCR9. CCR9 cells also
Immunity
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Figure 2. Tissue-Specific Homing Directed by Chemokines and Integrins Necessitates Appropriate Routes of Immunization for Protective
Mucosal Immunity
See text for details and references.
found that an attenuated SIV that replicates in the intesti- different from that of spleen DC (high amounts of IL-10)
(Iwasaki and Kelsall, 1999) (Figure 2). These DC subsetsnal mucosa induced CD8 CTL expressing another mu-
cosal homing receptor, E7, whereas cutaneous im- may play a role in selection of T cells primed in these
mucosal lymphoid organs. In addition, other recentmunization with a DNA vaccine and a recombinant
vaccinia virus did not induce expression of the E7 studies support the conclusion that DC in mucosal in-
ductive sites play an important role in imprinting gut-mucosal homing receptor (Cromwell et al., 2000). The
best local CD8 CTL response in the rectal mucosa homing potential in T cells (Campbell and Butcher,
2002b; Johansson-Lindbom et al., 2003; Mora et al.,can be achieved by oral or rectal inoculation of antigen
(Belyakov et al., 1998b). In contrast, parenteral routes 2003).
One additional possible route of antigen administra-of immunization were found to be best for the generation
of immune responses in systemic lymphoid tissues. tion that may result in effective mucosal immune re-
sponse is transcutaneous immunization. We recentlyTherefore, while systemic immunization might produce
limited mucosal immune responses by induction of im- found that the dissemination of immune response to the
mucosal sites (Peyer’s patches) after transcutaneousmune responses in lymph nodes that drain mucosa, the
most effective (protective) mucosal immune responses immunization can be explained by migration of antigen-
bearing dendritic cells, which are detected by their abil-can be generated after mucosal administration of a
vaccine. ity to stimulate a high-avidity CTL line. The migration of
dendritic cells from skin to gut mucosa is an importantLittle is known about what induces the different hom-
ing phenotypes in T cells activated in different microen- new concept that may be valuable in vaccine design
(Belyakov et al., 2004) (Figure 2). In contrast, it is unlikelyvironments. A recent study by Iwasaki and Kelsall indi-
cates that DC of PP can be of different phenotypes, that the T cells primed in the skin migrate to the gut
because T cells in the skin use different homing recep-such as myeloid DC (CD11b), lymphoid DC (CD8),
and double-negative (CD11b, CD8) (Iwasaki and Kel- tors. The chemokine receptor CCR4 on T lymphocytes
has been identified as a skin-homing receptor (Campbellsall, 2000), and that PP DC produced a cytokine profile
Review
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et al., 1999). One of the ligands of CCR4, CCL17, is site of toxins are designed to reduce the toxicity, but
retain the adjuvant effect (Cheng et al., 1999). Also, syn-expressed in inflamed skin but not mucosal tissues,
consistent with a role in tissue-specific trafficking. Cuta- ergistic combinations of cytokines (such as GM-CSF
and IL-12) (Ahlers et al., 2003; Belyakov et al., 2000),neous T cell-attracting chemokine (CTACK) is capable of
selectively attracting CLA cutaneous memory T cells. CpG-oligonucleotides (Klinman et al., 1999; Horner et
al., 2001; Krieg, 2002), or heat-shock protein linked withBoth CTACK and CCR4 are required for lymphocyte
recruitment in cutaneous delayed-type hypersensitivity HIV peptide (Lehner et al., 2000) manifested effective
mucosal adjuvant function (reviewed by Berzofsky et(Reiss et al., 2001).
These data underscore the functional consequences al., 2001).
In female rhesus macaques, after intravaginal inocula-of the substantial differences in homing receptor pat-
terns in mucosal versus systemic lymphocytes. Alterna- tion of SIV, SIV-specific CD8 intraepithelial lympho-
cytes were found predominantly in local vaginal tissues,tively, this asymmetry between mucosal and systemic
immunization can be explained by different migration especially in chronically infected monkeys (Lohman et
al., 1995). In macaques, the protection against rectalof DCs from mucosal and systemic antigen-presenting
sites. These two mechanisms are not mutually exclusive. SIV challenge correlates with activity of CD8 CTL in
the gut (Murphey-Corb et al., 1999). In recent studies,
it has been found that mucosal immunization of nonhu-Mucosal CD8 CTL and Antibody Responses
man primates leads to more effective induction of muco-Are Important for Protection against Mucosal
sal CTL and concomitantly more complete clearanceTransmission of HIV
of pathogenic SHIV from the gastrointestinal mucosa,Protection against oral and vaginal challenge has been
which is a major reservoir of SIV replication seedingdemonstrated by passive transfer of potent neutralizing
the bloodstream (Belyakov et al., 2001). Thus, mucosalIgG monoclonal antibodies into macaques (Baba et al.,
immunization more effectively reduced steady-state2000; Mascola et al., 2000). Infused IgG was detected
plasma viral load. Induction of CD8 CTL was correlatedat the mucosal surface, and vaccine-induced mucosal
with the level of CD4 T helper responses in immu-IgG or IgA could interrupt initial events associated with
nized macaques.mucosal transmission and regional spread of HIV-1
As discussed above, a local antibody and CD8 CTL(Kozlowski and Neutra, 2003). A number of mechanisms
response in the gut or cervicovaginal mucosa at the siteby which secretory IgA, produced by mucosal immune
of initial infection might provide an important comple-responses, can prevent transmission of HIV or SIV have
ment to systemic immunity by reducing viral load at thebeen described (reviewed by Kozlowski and Neutra,
portal of entry and by facilitating the clearance of virus2003). Also, HIV-specific CD8 CTL were found in the
from a major reservoir of viral replication (Belyakov etcervical mucosa of HIV-exposed seronegative prosti-
al., 2001; Berzofsky et al., 2001). Recent studies indicatetutes in Nairobi (Kaul et al., 2000). Thus, both mucosal
that some HIV-specific antibody and CTL responses inHIV-specific antibodies and CD8 CTLs have access to
mucosal sites and partial protection against mucosalsites of viral entry (cervicovaginal and rectal mucosa)
challenge with pathogenic SHIV can be induced afterand might play an important role for prevention of muco-
aggressive prime and boost strategies with systemicsal transmission.
HIV vaccines (reviewed by McMichael and Hanke, 2002).As noted, CD8 CTL must be present in the mucosal
However, the predominant weight of evidence is thatsite to prevent mucosal transmission of virus in mice,
mucosal HIV vaccines more effectively induce local mu-whereas systemic CTL were not sufficient (Belyakov et
cosal immune responses (in rectal and cervicovaginalal., 1998a). Only animals immunized intrarectally with
mucosa) and more effective clearance of virus from thean HIV vaccine, with measurable mucosal CTL, were
main site of replication in the gut and therefore shouldprotected against intrarectal challenge with a recombi-
be a major focus in developing a new generation ofnant vaccinia virus expressing HIV gp160 (Belyakov et
effective AIDS vaccines.al., 1998a, 1998b). These results, combined with the
asymmetry noted above between mucosal and systemic
compartments after different routes of immunization Conclusions
The ability to develop vaccines capable of protectingand the importance of local mucosal immunity to prevent
or reduce mucosal transmission suggests that mucosal against HIV is likely to depend on the induction of long-
term mucosal immune responses. The profound effectsvaccination may be critical for the most effective AIDS
vaccine. A number of different routes have been used to that HIV induces in systemic immunity have been well
characterized, but the situation with regards to mucosalinduce mucosal immune responses, including intranasal
immunization (Porgador et al., 1997), intrarectal im- immune responses is less clear. However, the mecha-
nisms of mucosal transmission, HIV pathogenesis in themunization (Belyakov et al., 1998c) (Klavinskis et al.,
1996), targeting the iliac lymph nodes (Lehner et al., intestinal mucosa, distribution of chemokine receptors,
and effector mechanisms of immune protection in mu-1996) (Klavinskis et al., 1996), intravaginal immunization
(Lehner et al., 1999) (Klavinskis et al., 1996), and transcu- cosal sites imply important differences from the sys-
temic response. This new understanding in mucosaltaneous immunization (Belyakov et al., 2004).
Mucosal immune responses and protection are highly immunology (molecular and cellular) comes at an oppor-
tune time to be exploited in the development of newdependent on mucosal adjuvants. Various truncated
and mutated bacterial toxins (cholera toxin and E. coli generation vaccines for HIV. Mucosal vaccines and mu-
cosal immunity, which reduce infection via HIV-specificlabile toxin) are currently used as mucosal adjuvants.
Modifications in the enzymatic active site or cleavage mucosal IgA and IgG responses and mucosal CD8CTL,
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The chemokine receptor CCR4 in vascular recognition by cutaneousshould be a significant part of the strategy for develop-
but not intestinal memory T cells. Nature 400, 776–780.ment of preventive and therapeutic HIV vaccines.
Cheng, E., Cardenas-Freytag, L., and Clements, J.D. (1999). The
role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labileAcknowledgments
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